This is investment research, not personal financial advice.

McBride plc (LSE:MCB) closed at £2.06 (206p), 23.06% higher on 28 August after announcing a manufacturing partnership with Vestacy. Volume reached 2.36 million shares, about 22 times its recent norm. The move added roughly £67.0 million to McBride's equity value in one session.

The announcement earned that reaction. It also pushed the share price straight into the part of the story that management does not expect to mature until H2 FY2028. The partnership sits inside a programme forecast to produce £170 million of annual revenue, with earnings growth broadly matching the revenue increase. Vestacy will supply £34 million of equipment. McBride expects to spend £17 million and carry an extra £25 million of peak net debt before cash generation begins (McBride Vestacy 2026).

The direction of the move looks justified. Its full size is front-loaded. At 206p, a reasonable base valuation already assumes the manufacturing transfer completes, the core business recovers from June's guidance cut, programme margins reach the group average and debt stops near management's estimate. That makes the 23% rise roughly proportionate, but only because the market has brought several years of execution into one day's price.

The tape bought FY2029 before FY2027 spending begins

The 28 August close was not a thin-market print. McBride opened at 183p, traded as high as 214.1p and closed at 206p, against 167.4p the previous day. The market therefore retained most of the early gain. At 173.56 million voting shares, confirmed in the latest repurchase filing, equity value rose from about £290.5 million to £357.5 million (Yahoo Finance 2026; McBride Shares 2026).

That £67.0 million increase should be compared with the cash and earnings disclosed in the release. McBride's own project and equipment cost is £17 million. The expected peak debt increase is £25 million once working capital is included. If the £170 million mature revenue runs at FY2025's 7.1% adjusted operating margin, it would produce about £12 million of adjusted operating profit. The share-price response was thus four times the disclosed McBride investment and more than five times an illustrative mature annual profit contribution.

Those comparisons do not make the move irrational. A multi-year contract has value beyond one year's profit, and customer-funded equipment reduces the capital McBride must provide. They do show what changed. Investors did not merely capitalise next year's earnings. They revalued the duration, asset intensity and strategic credibility of McBride's contract-manufacturing business.

The timing matters. FY2026 guidance is unchanged. Implementation costs begin in FY2027, revenue phases in through FY2027 and FY2028, full capacity is expected in early calendar 2028, and FY2029 is the first year with a complete contribution. Peak debt arrives before the mature earnings. The price has moved first; the cash bridge will take two reporting cycles to appear.

£170 million is larger and less simple than the headline

McBride signed two manufacturing agreements with Vestacy for terms of five to eight years. It also agreed to acquire dedicated plants in Spain and Portugal for nominal consideration, subject to conditions and works-council processes. Production will span those sites and McBride facilities in Belgium, Italy, Poland, the United Kingdom and France. The volume covers products Vestacy currently makes itself and products supplied by another manufacturer (McBride Vestacy 2026).

The programme's scale is plain. £170 million equals 18.3% of McBride's FY2025 revenue of £926.5 million. Contract manufacturing was 13.6% of group revenue that year, about £126 million. If the full programme is additive, that channel would move above the 25% mix goal presented at McBride's 2024 Capital Markets Day (McBride 2025; McBride CMD 2024).

But £170 million is not described as Vestacy revenue alone. The release says the Vestacy agreement reaches that figure when combined with other contracts being signed in parallel. It does not split those contracts, their customers, durations or economics. The Vestacy relationship is the trigger, while part of the quoted revenue comes from a wider pipeline.

Nor is the asset transfer free in an economic sense. Nominal consideration says little about employee obligations, maintenance backlogs, environmental remediation, leases or restructuring. The release excludes any fair-value accounting adjustments from current expectations. Vestacy's £34 million equipment contribution is valuable, yet the agreement does not state who owns the equipment, who funds replacement, or what happens to it when the contracts expire.

Pricing protection is better than McBride has often secured. Quarterly mechanisms should shorten the lag between energy, feedstock or packaging inflation and customer prices. They cannot prevent a lag inside each quarter, an efficiency miss, or a dispute over the cost index. The legal duration gives visibility. The missing minimum volumes and termination protections determine how much of that visibility is firm.

McBride's six-year record explains the 23% reflex

McBride makes private-label and contract-manufactured cleaning products in liquids, unit doses, powders, aerosols and related formats. Retailers and branded groups outsource formulation, procurement, production and packaging to the company. Scale can lower purchasing and factory costs, but contracts remain exposed to volatile inputs and powerful customers.

The financial record shows both sides.

Period Revenue (£m) Reported operating profit (£m) Net debt (£m) Adjusted ROCE* Net debt / adjusted EBITDA
FY2021 682.3 15.5 118.4 11.5% 2.6x
FY2022 678.3 (26.7) 164.4 (11.4)% (45.7)x**
FY2023 889.0 10.3 166.5 6.4% 4.9x
FY2024 934.8 64.3 131.5 33.5% 1.5x
FY2025 926.5 60.2 105.2 33.0% 1.2x
H1 FY2026 475.2 28.3 120.6 30.8% 1.4x***

*The schema field roic_pct carries McBride's directly reported adjusted return on capital employed, which uses adjusted operating profit and average period-end operating capital. It is not a standard NOPAT ROIC. **FY2022's negative EBITDA makes the reported debt multiple economically meaningless. ***H1 FY2026 leverage is author-computed as £120.6 million economic net debt divided by £85.9 million last-twelve-month adjusted EBITDA. Annual figures come from the five fetched annual reports; the interim row comes from the December 2025 filing (McBride 2021; McBride 2022; McBride 2023; McBride 2024; McBride 2025; McBride H1 2026).

FY2022 is the reason quarterly pricing carries weight. Input-cost inflation was running above £200 million on an annualised basis by the fourth quarter, while customer increases lagged repeated cost waves. Reported operating loss reached £26.7 million and debt rose £46 million. One year later, revenue had jumped 31% as pricing caught up, yet returns and leverage were still weak (McBride 2022; McBride 2023).

FY2024 delivered the repair. Reported operating profit rose to £64.3 million and debt fell £35 million. FY2025 held most of the margin while debt fell again. Customer service reached 94%, contract-manufacturing volumes grew 48.9%, and adjusted ROCE stayed above 30%. That operating recovery explains why a large, customer-funded contract won credibility rather than being dismissed as low-margin volume.

The recovery had already met fresh resistance. On 12 June 2026, McBride cut FY2026 and FY2027 adjusted operating-profit expectations by 5% to 10% after Middle East disruption raised energy and feedstock costs faster than customer pricing could respond. The same release said the Eurotab acquisition remained strategically sound, but Eurotab's final purchase value was later reduced because expected EBITDA had fallen (McBride June 2026; McBride Eurotab 2026).

Vestacy arrived eleven weeks after that reset. The contract supplied a long-duration growth line when the market had just marked down the core. That sequence amplified the reaction.

A scale moat without much pricing power

McBride's defensibility sits in operations. It has plants, laboratories, regulatory files and retailer relationships across Europe. A customer can source liquids, powders, tablets and aerosols through one network. Production can shift among countries, and large runs spread formulation, procurement and compliance costs across more units.

FY2025 private-label household share was 35.5%. The top ten customers supplied 53% of group revenue, though no customer exceeded 10%. Those figures indicate both reach and bargaining concentration. McBride is embedded in retailer supply chains, but the retailers retain substantial power (McBride 2025).

Vestacy strengthens the operational side of that moat. A branded owner is transferring lines from its own plants and from another supplier. Seven-country production creates redundancy and lets McBride place products near available capacity. The two transferred sites and £34 million of customer-funded equipment also deepen the relationship.

The economics remain manufacturing economics. Reckitt reported roughly £2.0 billion of 2024 net revenue and £490 million of adjusted operating profit for Essential Home before selling control to Advent, leaving Vestacy with a branded portfolio and much higher margins than McBride. McBride receives throughput and service revenue. Vestacy retains the brand and most consumer pricing power (Reckitt 2025).

Private label supplies a separate demand support. NielsenIQ data published by PLMA put private label at 38.7% of sales value across 17 European markets in late 2025. Germany, the UK and France together reached 40.3%. Home-care direction varied by region, so this is not a uniform category boom, but household budget pressure continues to favour retailer brands (PLMA and NIQ 2025).

Energy works against that demand tailwind. Eurostat estimated euro-area inflation at 2.9% in July 2026, with energy inflation at 10.0%. Higher utility and logistics costs squeeze McBride before repricing while also pushing households toward lower-priced products. The company benefits from trade-down and suffers from the cost shock that helps cause it (Eurostat 2026).

The moat is therefore stable rather than absolute. Scale, service and technical knowledge improve the odds of winning long contracts. They have not removed pricing lags or customer power. Vestacy widens the network; it does not turn McBride into a brand owner.

Owner cash is thinner than the company's free cash flow

McBride's alternative free-cash-flow measure starts before interest, tax and capital expenditure. FY2025 free cash flow of £93.9 million was cash generated from operations before exceptional items. That number is useful for cash conversion from EBITDA, but it is not cash available to owners.

The statutory and alternative cash disclosures allow a more demanding bridge.

FY2025 owner-cash bridge £m
Reported free cash flow to equity 26.7
Remove working-capital release (13.7)
Normalise pension funding from £7.0m to about £5.7m 1.3
Add back refinancing cash 1.8
Normalise £30.4m capex toward £25m-£30m 0.4 to 5.4
Charge share compensation as an economic cost (1.6)
Author-estimated normal owner cash 14.9 to 19.9

The starting £26.7 million already deducts interest, tax, capex, lease principal and pension funding. Removing the working-capital release prevents a favourable unwind from becoming a permanent earning assumption. The resulting £15 million to £20 million range fits a separate run-rate bridge from EBITDA less maintenance investment, cash tax, interest, leases, pensions and recurring exceptional costs (McBride 2025; McBride CMD 2024).

That is a 4.2% to 5.6% owner-cash yield on the post-event equity value. It is far below the headline conversion implied by £93.9 million. Vestacy can improve owner cash after maturity, but FY2027 transition costs and inventory will push the other way first.

Capital allocation adds pressure. McBride resumed dividends after the balance-sheet repair and launched a £20 million repurchase programme in November 2025. It completed Eurotab for a €35.6 million enterprise value in July 2026, using facilities. Vestacy follows with another £17 million of project spending and a £25 million expected peak debt draw. Each decision can be rational by itself. Together they consume the headroom created in FY2024 and FY2025.

Vestacy clears cost of capital on two different denominators

A 7% adjusted operating margin on £170 million gives £11.9 million of mature EBIT. Applying a 30% tax rate gives £8.33 million of NOPAT. Both are author calculations, not guidance. Management only said earnings should rise broadly in line with revenue.

The return depends on which capital belongs in the denominator.

Capital base Interpretation EBIT return Post-tax return
£17m McBride's stated project and equipment spend 70.0% 49.0%
£25m Expected peak debt funding, including working capital 47.6% 33.3%
£51m McBride spend plus Vestacy-funded equipment 23.3% 16.3%
£59m Peak funding plus Vestacy-funded equipment 20.2% 14.1%

The £17 million and £25 million should not be added together because peak debt already includes project costs, inventory and timing. The £51 million and £59 million rows are economic-asset sensitivities. They ask what the project earns if customer-funded equipment is counted as productive capital even when McBride does not finance it.

At the narrow McBride cash denominator, the contract earns 33% to 49% after tax at a 7% margin. Even the full economic-asset view yields 14% to 16%, which can exceed a reasonable industrial cost of capital. This is the strongest argument for the market's reaction.

Margin decides the spread. At 3%, NOPAT is £3.57 million and the return on £59 million is only 6.1%. At 9%, NOPAT reaches £10.71 million and the same return is 18.2%. Quarterly repricing, utilisation, inherited-site costs and equipment ownership determine which row is relevant.

Incremental ROIC for the group cannot yet be measured because neither invested capital nor Vestacy NOPAT exists in the accounts. The table is a forward project-return sensitivity. The first honest group calculation will need FY2028 capital employed, programme earnings and the cash absorbed during ramp.

Debt arrives before earnings

At 31 December 2025, McBride reported £120.6 million of economic net debt. Its banking covenant measure was only £39.3 million because £75.2 million of factoring and £6.8 million of leases sat outside banking debt. Liquidity was £135.3 million, including £112.9 million of revolving-facility headroom. The €200 million revolving facility runs to November 2029 after an extension (McBride H1 2026).

Eurotab changes that balance. The €35.6 million enterprise value was reported as £30.7 million at completion. Adding that amount to the December debt gives a rough acquisition-adjusted proxy of £151.3 million before FY2026 cash generation, buybacks and closing adjustments. It is not a current balance-sheet claim; the June 2026 accounts have not been filed.

Adding Vestacy's £25 million expected peak gives £176.3 million. Against £85.9 million of last-twelve-month adjusted EBITDA, that is 2.05 times. Including an illustrative £15 million of mature Vestacy EBITDA reduces it to 1.75 times. The debt therefore rises above McBride's sub-1.5-times ambition before the programme can pull it back.

Working capital is the largest unknown. McBride's Capital Markets Day used roughly 10% of sales as a normal trade-working-capital reference. Ten per cent of £170 million is £17 million. Add the disclosed £17 million implementation and equipment spend and gross funding reaches £34 million. Management's £25 million peak implies about £9 million of timing, supplier, customer or internal-cash offsets.

A simple stress raises working capital to 15% of revenue and the £17 million implementation bill by 20%. Gross funding becomes £45.9 million. After the same £9 million offset, peak debt is £36.9 million, almost £12 million above guidance. One additional month of receivables adds about £14 million. Liquidity can absorb that in isolation, but Vestacy is running beside Eurotab integration, SAP implementation, pensions and shareholder distributions.

The balance sheet is not in immediate danger on the disclosed numbers. The risk is loss of flexibility. A delayed ramp would keep debt elevated while the core business remains exposed to energy and pricing shocks.

£2.06 asks for a complete ramp and a recovered core

An enterprise-value-to-EBIT framework fits McBride better than a sales multiple. Revenue is large relative to margin, working capital matters, and customer-funded assets complicate capital intensity. The model below uses reported economic debt rather than the narrower banking covenant definition.

At 206p, equity value is £357.5 million. Adding £120.6 million of December net debt gives £478.1 million of enterprise value. Adding Eurotab's £30.7 million as a conservative proxy raises it to £508.8 million before pension obligations. Against £65.6 million of last-twelve-month adjusted EBIT, the first figure is 7.3 times. Against a £63.5 million to £67.1 million FY2027 range implied by June's 5% to 10% reduction to company-compiled consensus, the second is 7.6 to 8.0 times (McBride June 2026).

A reverse valuation makes the embedded contract assumption visible. Take £68 million of core FY2028 EBIT, £176.3 million of debt, a 7.5-times exit multiple, a 10% equity discount rate and two years to maturity. For today's price to compound at that rate, FY2028 enterprise value must reach about £608.9 million. Required EBIT is £81.2 million. Vestacy and the parallel contracts must therefore add £13.2 million, equal to a 7.8% margin on £170 million.

At an 8-times multiple, the required programme margin falls to 4.8%. At 7 times it rises to 11.2%. This spread makes the durable group multiple as important as contract profit.

Mature programme revenue / EBIT margin 3% 5% 7% 9%
£85m, 50% of plan £1.68 £1.74 £1.80 £1.86
£127.5m, 75% of plan £1.73 £1.82 £1.91 £2.00
£170m, full plan £1.77 £1.89 £2.01 £2.14
£187m, 110% of plan £1.79 £1.92 £2.06 £2.19

These author-calculated values assume core EBIT of £68 million, debt of £176.3 million, a 7.5-times multiple and a 10% discount rate. A two-point contract-margin change at full revenue moves value by about 12p to 13p. A one-turn change in the group multiple has a larger effect.

The four scenarios widen both variables. Severe downside assumes transfer problems, weak core earnings and a 4.5-to-5.5-times multiple, producing 33p to 58p. The bear case allows partial volume and a 4% programme margin, giving £1.03 to £1.34. The base case reaches full revenue at 7% with core EBIT of £68 million, giving £1.82 to £2.20. The bull case needs revenue above plan, a 9% margin, core EBIT of £73 million and debt reduction, giving £2.68 to £3.12.

The 206p close sits near the base-case centre. It does not require the bull case. It does require most of the base case.

The anti-thesis sits in the contract's blank spaces

The strongest counterargument starts with contract duration. At a 7% margin and 30% tax, mature NOPAT is £8.33 million. Discounting a level five-to-eight-year stream from the expected maturity date at 10% gives roughly £26 million to £37 million today. Deducting £17 million of disclosed McBride spend leaves £9 million to £20 million, or about 5p to 11p per share. Using £25 million of peak capital lowers the range further.

This finite-contract calculation is deliberately conservative. It gives no credit for ramp cash, recovered working capital, residual equipment, renewals or strategic follow-on work. But the market added 38.6p per share. Renewal value, a higher multiple on core earnings or additional contracts must do most of the remaining work.

The second gap is concentration. FY2025 contract manufacturing was about £126 million. Adding £170 million would make it roughly 27% of a simple £1.10 billion pro-forma group. The new programme alone would be around 15.5% of that revenue. Duration improves visibility while Vestacy's bargaining weight grows.

The third is simultaneous execution. McBride must transfer two sites, fit Vestacy equipment across several countries, integrate Eurotab and continue SAP work. Eurotab's price adjustment showed transaction discipline, because McBride paid less after the target's expected EBITDA fell. It also showed how quickly a forecast operating base can change.

Management deserves credit for repairing the FY2022 balance sheet and delivering FY2024 and FY2025 cash. The June 2026 warning is counter-evidence. A new energy shock again outran pricing, even after the lessons of FY2022. Quarterly Vestacy resets improve the mechanism but do not prove the margin.

This leaves a balanced verdict. The announcement changed McBride's capital efficiency, duration and strategic mix enough to justify a material rerating. The 23% close looks roughly proportionate only if the programme reaches group economics and the core recovers. The price response looks excessive under a finite, no-renewal contract view.

Three reporting dates will settle the reaction

The first checkpoint is early 2027. McBride expects the Spanish and Portuguese acquisitions to complete then. The relevant disclosures are not the nominal purchase price; they are transferred employees, leases, environmental provisions, restructuring costs, equipment ownership and the split of the £170 million between Vestacy and parallel contracts. A delay past the FY2027 half-year report would put the early-2028 capacity date under pressure.

The second checkpoint is the FY2027 cash-flow statement. Vestacy implementation and working-capital debt above £35 million would exceed the £25 million estimate by enough to weaken the capital-efficiency case. Economic net debt above two times adjusted EBITDA, including factoring and leases, would show that Eurotab, distributions and the programme have used most of the balance-sheet repair.

The third checkpoint spans FY2028 and FY2029. Annualised programme revenue should exceed £100 million entering FY2028 if full capacity is to arrive in early calendar 2028. Once more than half the volume is running, a group adjusted operating margin below 6% would suggest pricing, utilisation or transition costs are diluting the economics. Contract manufacturing should move above 20% of group revenue on the way to the strategic target.

The market now prices a successful transfer, a group-level programme margin and a recovered core business. The contracts run for years, but the next two results will show whether the £25 million debt peak and early-2028 capacity date still belong in the same model.

Source notes

Verification is partial. The point-in-time Finance API health and authentication checks passed, but its exact-entity resolver returned no LSE match for MCB at the 28 August cutoff. Identity was therefore confirmed manually against Companies House, McBride's annual-report cover and company number 02798634. Price, previous close, move and volume were reconciled to Yahoo Finance's daily tape; shares came from McBride's 24 August repurchase RNS. A TradingView discovery feed reported an inconsistent £275.4 million market capitalisation, implying only 133.7 million shares, so it was rejected. The article uses £357.5 million, computed from 206p and 173.56 million shares.

All six financial rows come from fetched primary reports. The roic_pct field maps McBride's reported adjusted ROCE to the schema's industrial return field, and the H1 FY2026 leverage ratio is author-computed from economic net debt and last-twelve-month adjusted EBITDA. Owner cash, project returns, reverse valuation, sensitivity values and scenario ranges are author calculations. They should not be read as company forecasts. Vestacy has not disclosed minimum volumes, termination compensation, the programme revenue split, factory liabilities or equipment title, so those items remain the main evidence gaps.

References